To determine whether long-term daily consumption of milk containing probiotic Lactobacillus rhamnosus GG (GG) decreases respiratory illness in children. SUBJECTS/METHODS: A randomized, double-blind, placebo-controlled trial was conducted with 523 children aged 2-6 years attending day care centers in Finland. Subjects received either normal milk or the same milk with GG on three daily meals for 28 weeks. Daily recording of childrens' symptoms was done by parents. Primary outcome data from 501 subjects were available for analysis, and data from 128 subjects were analyzed as completed cases in terms of recovery of GG in fecal samples. RESULTS: Number of days with at least one respiratory symptom in all subjects was 5.03/month (95% confidence interval (CI): 4.92-5.15) in the GG group and 5.17/month (95% CI: 5.05-5.29) in the placebo group incidence rate ratio (IRR) 0.97; 95% CI: 0.94-1.00; P ¼ 0.098). In the completed cases, the figures were 4.71 days/month (95% CI: 4.52-4.90) in the GG group and 5.67 days/ month (95% CI: 5.40-5.94) in the placebo group (IRR 0.83; Po0.001). CONCLUSIONS: Consumption of GG reduced the occurence of respiratory illness in children attending day care centers in the completed cases subgroup, but not in the total population. Thus, future clinical trials are warranted to clarify the association between fecal recovery of a probiotic and the symptom prevalence.
INTRODUCTION
Respiratory and gastrointestinal infections are the most common illnesses in children, with day care center attendance promoting an increased risk of disease. 1 In systematic reviews, probiotics have been concluded to be beneficial in the treatment of infectious diarrhea, 2 and more recently in the prevention of acute upper respiratory tract infections. 3 However, as the health effects of probiotics are always strain-specific, the evidence is still limited for evaluation of the most effective strains, especially in the case of respiratory diseases. Lactobacillus rhamnosus GG (GG) has shown promising results in respiratory symptom reduction. [4] [5] [6] To evaluate the effects of GG, we conducted a randomized, double-blind, placebo-controlled trial with the aim of evaluating the effect of 28-week consumption of GG on respiratory illness in children attending day care centers.
SUBJECTS AND METHODS

Study design
This randomized, double-blind, placebo-controlled trial was carried out between September 2009 and May 2010 in Kainuu and Oulu regions in Finland. After a run-in period of 2-3 weeks without the consumption of probiotic products, the children consumed GG or placebo milk three times a day for 28 weeks from October to April. The study protocol was approved by the Ethics Committee of Joint Authority of Kainuu Region. Study was registered to http://clinicaltrials.gov with identifier NCT01014676.
Subjects
Sixty-day care centers in Kainuu and Oulu regions in Finland participated in the study and children attending to day care 5 days a week and aged 2-6 years were recruited through meetings with parents. Children with milk allergy, lactose intolerance, congenital heart disease requiring regular medication, malignant diseases, cytostatic treatment, use of biological rheumatic medication, continuous microbial medication, regular use of oral corticosteroids, diabetes or simultaneous participation in other clinical trials were excluded from the study.
Randomization
The randomization was performed by the statisticians who had no contact with study subjects. Each child was randomly allocated to the probiotic group or placebo group according to a computer-generated randomization list. Randomization was stratified according to age (2, 3, 4, 5 and 6 years) and gender.
Data collection
Before the study began, parents filled out a questionnaire collecting information on the child's living environment and family, nutrition, health and history of illnesses. Throughout the intervention period parents made daily recording of child's respiratory symptoms (fever, runny nose, 1 Valio Ltd, Helsinki, Finland; stopped-up nose, sore throat, cough, increased mucus production, wheezing, ear ache and eye discharge) and gastrointestinal symptoms (diarrhea, vomiting, constipation, flatulence and abdominal pain).
When a subject had symptoms of respiratory or gastrointestinal infection that, according to parents' judgement, required physician's contact, parents were advised to take the child to a study physician. Study physicians were practitioners at private health centers who were familiarized with the study protocol. In addition to normal assessment and treatment, study physicians filled out a questionnaire of every visit, collecting information on symptoms, diagnosis and prescribed medications. In case the child was taken to a physician who was not involved in the study, parents were to request the physician to fill out diagnosis and prescribed medications to the study diary.
Study products and intervention
The GG product in this study was Gefilus milk, which is commercially available in Finland (Valio Ltd, Riihimäki, Finland). The milk contained 1% fat and the probiotic strain L. rhamnosus GG (The American Type Culture Collection 53103). The placebo milk had the same composition but without GG. The microbial content of the probiotic milk was verified from every batch by laboratory of the production plant (Valio Ltd) on the day of the production and at the end of the shelf life (production day þ 7 days). Amounts of GG in fresh milk ranged from 6.7 Â 10 5 to 1.9 Â 10 6 c.f.u./ml, whereas end-of-shelf life probiotic content ranged from 2.0 Â 10 5 to 1.2 Â 10 6 c.f.u./ml. The day care personnel served the study milks according to randomization on three daily meals at the day care centers, 5 days a week. Day care personnel recorded the amount of milk consumed by each child on all meals. For the days off from day care (weekends, holidays and sick leaves), parents were advised to serve the milk to the child at home according to equivalent routine and to record the consumed amounts to the study diary. The aim was to offer study milk on three meals daily, and to allow the child to continue usual milk drinking habits in terms of the amount of milk consumed.
Collection and analysis of fecal samples
Fecal samples were collected at baseline (during the week before the intervention started, following a minimum of 2 week restriction from consumption of probiotic-containing products), and at the end of the intervention period (during the last week of the intervention). Fecal samples were collected at home and parents were advised to take samples immediately to the study center, where samples were stored at À 70 1C until analysis. Strain-specific real-time quantitative PCR assay was used to quantify GG in fecal samples according to a published method. 7 Fecal samples were analyzed from subjects who provided both baseline and end-of study fecal samples.
Outcome measures
Primary outcome measure of the study was rate of respiratory illness in children, which was assessed by number of days with respiratory symptoms, number and duration of respiratory symptom episodes, number of diagnosed respiratory tract infections and number of antibiotic treatments. Gastrointestinal symptoms were considered secondary outcomes.
Subject was considered having a day with respiratory symptoms whenever the child experienced, according to parents' judgement, one or more of the following symptoms: fever, runny nose, stopped-up nose, sore throat, cough, increased mucus production, wheezing, ear ache or eye discharge. A subject was considered to have a respiratory symptom episode when the child had at least one respiratory symptom on two consecutive days or at least two symptoms on 1 day with at least 7 days without respiratory symptoms between two episodes. If the number of symptom-free days was less than seven, the symptoms were considered part of the previous episode. In diagnosis of respiratory tract infections, study physician were instructed to continue their normal clinical practise in diagnosing children.
With secondary endpoint, gastrointestinal symptoms, symptom day was defined as any day with one or more of the following symptoms: diarrhea, vomiting, constipation, flatulence or abdominal pain.
Statistical analysis
Sample size was calculated based on a previous study 4 where number of days with respiratory symptoms in children aged 2-6 years was 30 (s.d. ¼ 26) in the placebo group during the 7-month intervention. It was assumed that the use of L. rhamnosus GG would result in a 20% reduction in number of days with respiratory symptoms. Thus, the total sample size of about 600 children (300 in each group) was estimated to detect a difference of 20% between study groups with a power of 85% and at a significance level of 0.05.
The data are presented as counts with percentages, means with s.d. or medians with interquartile ranges (IQRs). The most important outcomes are given with 95% CIs. The comparison between groups in dichotomous outcomes was made by w 2 test. Number of episodes or symptom days per month, incidence rate ratios and P-values between groups concerning these outcomes were calculated by Poisson regression models.
RESULTS
Recruitment and participant flow
The intervention was set to start in the beginning of October 2009 before the peak respiratory infection season. Owing to limited time available for the recruitment, the goal of 600 children could not be met. In all, 523 children were randomized to the trial with 261 allocated to receive milk with GG (GG group) and 262 to receive the same milk without the probiotic (placebo group). Data from 501 subjects were available for analysis (Supplementary Figure 1) . Mean follow-up time for the subjects included in the analysis was 26.0 weeks (s.d. ¼ 6.6) in the GG group and 25.8 weeks (s.d. ¼ 6.4) in the placebo group.
Baseline demographics
The groups were similar in terms of baseline characteristics except for more atopic eczema diagnosed by a physician in the placebo group (18%) than in the probiotic group (8%) and more adenoidectomies had been performed to children in the probiotic group (14%) than in the placebo group (10%) ( Table 1) .
Study product consumption
The mean daily milk consumption was 400 ml (s.d. ¼ 100) in both groups. This means that the average daily probiotic consumption in the GG group was B10 8 c.f.u., taking into account the differences in the GG content of fresh and end-of-shelf-life milks.
Recovery of GG in fecal samples Fecal samples were received from 67% (336/501) of children at baseline and from 66% (296/450) of children at the end of the intervention. Fecal recovery of GG was measured from all subjects who provided both baseline and end-of-study fecal samples (119 in the GG group and 98 in the placebo group). Strain-specific detection limit for GG was 5.5 log 10 genome copies/g. Number of samples in which GG was recovered and the concentrations of GG positive samples are shown in Table 2 . In the GG group, GG was below the detection limit before the intervention and above the detection limit at the end of the intervention in 68% (81/119) of the subjects from whom both samples were analyzed. Similarly, 48% (47/98) of subjects in the placebo group had GG below the detection limit in both samples. These subjects (n ¼ 128) were considered completed cases in terms of recovery of GG in fecal samples.
Primary outcomes During the 28-week intervention period, the number of days with at least one respiratory symptom was 5.03/month (95% confidence interval (CI): 4.92-5.15) in the GG group and 5.17/month (95% CI: 5.05-5.29) in the placebo group (incidence rate ratio (IRR) 0.97; 95% CI: 0.94-1.00; P ¼ 0.098) in the 501 children from whom primary outcome data were available.
Number of respiratory symptom episodes per month was 0.59 (95% CI: 0.55-0.63) in the GG group and 0.55 (95% CI: 0.52-0.59) in the placebo group (IRR 1.06; 95% CI: 0.96-1.16; P ¼ 0.24). In all, 95% (239/251) of the children in the GG group and 94% (236/250) in the placebo group had at least one respiratory symptom episode during the intervention, median duration being 8 days (IQR 5, 12) in both groups. Also, 48% (121/251) of the children in the GG group and 49% (122/250) in the placebo group had at least one health care visit with respiratory infection diagnosis during the intervention period (P ¼ 0.89). Further, 35% (89/251) of children in the GG group and 34% (86/250) in the placebo group were prescribed antibiotics at least once during the intervention (P ¼ 0.80), median number of treatments being 1 (IQR 1, 2) Secondary outcomes Number of days per month with at least one gastrointestinal symptom was 0.93 (95% CI: 0.88-0.98) in the GG group and 0.95 (95% CI: 0.90-1.00) in the placebo group (IRR 0.98; 95% CI: 0.91-1.05; P ¼ 0.52).
Analysis on the completed cases based on recovery of GG in fecal samples Analysis on the number of days with at least one respiratory symptom was also performed on the previously identified completed cases subgroup in terms of compliance assessed by detection of GG in the fecal samples of children from whom fecal samples were received before and at the end of the intervention (n ¼ 128). In this population the mean number of days with at least one respiratory symptom was 4.71/month (95% CI: 4.52-4.90) in the GG group and 5.67/month (95% CI: 5.40-5.94) in the placebo group (IRR 0.83; 95% CI: 0.78-0.88; Po0.001). Children in the GG group and in the placebo group were similar in terms of baseline characteristics also in the completed cases subgroup. However, in subjects randomized to receive GG, children in the completed cases subgroup were older than the rest of the children in this study group (mean 4.3 (s.d. ¼ 1.3) vs 3.9 (1.3), P ¼ 0.031). There were no other significant differences in the baseline characteristics between the children considered completed cases and the rest of the children in the study, either in children randomized to receive GG or placebo.
Safety
Parents contacted study personnel to report altogether 22 adverse events during the intervention (GG ¼ 8, placebo ¼ 14). Of these reported events 15 were related to gastrointestinal problems such as nausea or abdominal pain (GG ¼ 5, placebo ¼ 10) and seven to skin problems such as rash (GG ¼ 3, placebo ¼ 4). None of the reported adverse events were serious.
DISCUSSION
In this randomized, placebo-controlled, double-blind trial, statistically significant reduction in the occurrence of respiratory or gastrointestinal illness in children attending day care centers was not achieved with the 28-week consumption of milk containing GG. However, a completed cases subgroup analysis based on recovery of GG in fecal samples showed a statistically significant reduction in days with at least one respiratory symptom, children in the GG group having approximately one respiratory symptom day less per month compared with children in the placebo group. On secondary outcome, gastrointestinal symptoms, no difference was observed between the groups.
Strongest results in respiratory symptom reduction with GG in children have been demonstrated in the studies by Hojsak et al. 5, 6 Both of these studies have used daily dose of 10 9 c.f.u. whereas more modest effects in symptom reduction have been demonstrated in the study by Hatakka et al. 4 and this trial where average daily dose of GG has been 10 8 c.f.u. Existence of dose-response of GG has previously been studied in the treatment of gastrointestinal infections, where difference in the health effects achieved between the studied doses was not demonstrated. 8 However, both of the studied doses were Table 2 . Number of fecal samples with L. rhamnosus GG above the detection limit (5.5 log 10 genome copies/g) and concentrations of L. rhamnosus GG in these samples analyzed by strain-specific real-time quantitative PCR method (expressed as median log 10 genome copies/g) 
132 ( (8) 44 (18) Physician diagnosed food allergy, n (%)
7 (3) 12 (5) Adenoidectomy, n (%) 36 (14) 26 ( higher (10 10 and 10 12 c.f.u./day) than the ones used in the trials on respiratory illness, thus no data are available on the doseresponse of the lower doses. Beneficial effects of probiotics are likely to be mediated through the gut mucosal immune system, by modulation of innate and adaptive immune responses, but also direct antimicrobial effects and improvement in mucosal barrier function have been demonstrated. 9 In this study the relatively high number of children with GG recovered from the feces in the beginning of the intervention and the number of incompliant children or children with GG colonization persisting throughout the trial might have weakened the results, as it is not known how small doses of a probiotic and what frequency of dosing might be able to induce antimicrobial effects or affect the gut mucosal immune system in vivo at least to some extent. The results on gastrointestinal symptoms in this study are in line with what has been observed in previous trials on GG in healthy children, with no difference between the groups observed. 4, 5 Thus, this study strengthens the evidence on GG not being effective in reducing gastrointestinal symptoms in healthy children, although effect of GG supplementation is evident in, for example, treatment of infectious diarrehea. 2 In terms of milk consumption, very good compliance was achieved in this trial as children consumed on average 400 ml of study milk daily in both groups. It also seems that there were no errors in the study product allocation in the day care centers as 95% of the children in the GG group had the probiotic recovered from the end-of-study fecal sample. However, at the end of the trial GG was also recovered in the fecal sample of 31% of the children in the placebo group. This could be due to the fact that products containing GG are widely available in Finland as nearly all grocery stores and pharmacies sell products containing GG. Therefore, the children in the placebo group might have unintentionally consumed GG during the trial even though list of products containing GG were given to all families to help avoidance of these products. In addition, the rate of subjects from whom GG was recovered in the beginning of the intervention was high, which indicates that the run-in period in our trial was too short in duration to clear the GG as 34% of subjects still carried GG in the beginning of the intervention. This is consistent with a recent study, which found that in 28% of the subjects GG was recovered from the fecal sample at the end of the 3-week followup period without probiotic product consumption. 10 These results demonstrate that the length of the run-in period is very crucial when trials are conducted in areas where the studied probiotic strain is commercially widely available.
We are aware of limitations in our study. In addition to the aforementioned issues on compliance and the adequate length of the run-in period, method of monitoring the symptoms and infections is another key matter in this study. The method for the daily monitoring of respiratory symptoms (questionnaire in the form of a study diary) used in this trial has not been validated. We chose to use this form of symptom monitoring, as the same method has been used in previous trial with similar trial setting, 4 and because to our knowlede no generally accepted validated method for daily respiratory symptom collection on children is available. To collect respiratory symptom data in clinical trials more systematically and to obtain more easily comparable data, it would be of great relevance to have a validated method for respiratory symptom data collection in children for future clinical trials.
In this trial, long-term consumption of L. rhamnosus GG reduced the occurrence of respiratory illness in children attending day care centers only in the completed cases subgroup analysis based on recovery of GG in fecal samples. We encourage future trials with screening of subjects based on recovery of GG in fecal samples before enrollment in the trial. Careful selection of countries in which trial is conducted should also be taken into consideration, because wide availability of GG in a range of products can make the avoidance of GG containing products very challenging for the subjects. Dose-response setting to identify the required dose of GG for respiratory symptom reduction in children is also warranted.
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